Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis.

[Guest guest]

Ann Rheum Dis 2001 Jan;60(1):67-68

Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing

erosive arthritis in patients with systemic lupus erythematosus and rheumatoid

arthritis.

Mediwake R, Isenberg DA, Schellekens GA, van Venrooij WJ

Centre for Rheumatology/ Bloomsbury Rheumatology Unit, Department of Medicine,

University College London, UK.

[Record supplied by publisher]

OBJECTIVES: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) can

both present with an erosive arthritis with the small joints of the hands

affected. Therefore a serological marker would be useful to distinguish between

these two diseases at onset. In this study anti-RA33 antibodies, which are found

in patients with SLE and RA, and anti-citrullinated peptide antibodies

(anti-CCP), which have recently been described as highly specific for RA, were

assessed. METHODS: Two hundred and thirty one patients receiving long term

follow up for SLE were evaluated for arthritis and classified as erosive and

non-erosive disease. Sixty six patients were tested for anti-RA33 and anti-CCP

antibodies. All the patients were tested for rheumatoid factor (RF) and HLA-DR4

status. RESULTS: Ten patients had erosive disease, six of whom were RF positive

(60%), and six anti-RA33 positive (60%), whereas only two were anti-CCP positive

(20%). Two hundred and twenty one patients had non-erosive disease, 40 of whom

were RF positive (18%), 14 were anti-RA33 positive (6%), whereas only one

patient was found to be anti-CCP positive (0.5%). CONCLUSION: The presence of

anti-CCP antibodies may be useful in distinguishing RA from erosive SLE.

Anti-RA33 antibodies and RF are unhelpful.

PMID: 11114286

[Guest guest]

It's about time!

----- Original Message -----

From: " a " <aA@...>

<egroups>

Sent: Monday, January 01, 2001 6:31 PM

Subject: [ ] Use of anti-citrullinated peptide and anti-RA33

antibodies in distinguishing erosive arthritis in patients with systemic

lupus erythematosus and rheumatoid arthritis.

> Ann Rheum Dis 2001 Jan;60(1):67-68

> Use of anti-citrullinated peptide and anti-RA33 antibodies in

distinguishing erosive arthritis in patients with systemic lupus

erythematosus and rheumatoid arthritis.

>

> Mediwake R, Isenberg DA, Schellekens GA, van Venrooij WJ

>

> Centre for Rheumatology/ Bloomsbury Rheumatology Unit, Department of

Medicine, University College London, UK.

>

> [Record supplied by publisher]

>

> OBJECTIVES: Systemic lupus erythematosus (SLE) and rheumatoid arthritis

(RA) can both present with an erosive arthritis with the small joints of the

hands affected. Therefore a serological marker would be useful to

distinguish between these two diseases at onset. In this study anti-RA33

antibodies, which are found in patients with SLE and RA, and

anti-citrullinated peptide antibodies (anti-CCP), which have recently been

described as highly specific for RA, were assessed. METHODS: Two hundred and

thirty one patients receiving long term follow up for SLE were evaluated for

arthritis and classified as erosive and non-erosive disease. Sixty six

patients were tested for anti-RA33 and anti-CCP antibodies. All the patients

were tested for rheumatoid factor (RF) and HLA-DR4 status. RESULTS: Ten

patients had erosive disease, six of whom were RF positive (60%), and six

anti-RA33 positive (60%), whereas only two were anti-CCP positive (20%). Two

hundred and twenty one patients had non-erosive disease, 40 of whom were RF

positive (18%), 14 were anti-RA33 positive (6%), whereas only one patient

was found to be anti-CCP positive (0.5%). CONCLUSION: The presence of

anti-CCP antibodies may be useful in distinguishing RA from erosive SLE.

Anti-RA33 antibodies and RF are unhelpful.

>

> PMID: 11114286